Abstract: The present invention relates to amino alcohol derivatives of general formula I: These derivatives possess an interesting activity in that they block the secondary products of lipid oxidative stress, and are consequently suitable for therapeutic use in all disorders related with the presence of reactive carbonyl compounds.

Abstract: The present invention provides new bi- and polypyridine ligands of ruthenium dyes. The invention also provides solar cells, in particular dye-sensitized solar cells comprising the dyes.

Abstract: The disclosure relates to Seebeck/Peltier effect thermoelectric conversion devices and in particular devices made of stack of dielectric layers alternated to treated semiconducting layers even of large size, not requiring lithographic patterning in a nano-micrometric scale.

Abstract: A method for producing electrical contacts on organic semiconductors is described. The method, which involves low energy impact and can be carried out under ambient conditions, comprises covering the relevant surface of the semiconductor with a layer of an appropriate solvent: a metal leaf having an appropriate thickness and work function containing metal oxide impurities is deposited onto the area treated in this manner. Electrical contacts with elevated conductivity are obtained by evaporating the solvent. One embodiment of the invention describes a family of crystalline semiconductors, preferably based on perylene or ?-quaterthiophene, provided with the electrical contacts according to the method described herein and provided with particular structural characteristics. The use of metal leaf satisfying the above-stated requirements (for example imitation gold leaf, gold leaf etc.). in the above-described method is furthermore described.

Abstract: The invention provides GPR17 modulators, methods of screening and use thereof for diagnosis and therapy of diseases or dysfunctions involving GPR17 activation, particularly ischemic brain damage.

Abstract: The method for preventing and delaying inherited retinal degenerations using serine palmitoyltransferase inhibitors, and compositions which contain them.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).

Abstract: Novel liposomes are described which are capable of effectively binding beta amyloid peptide and are useful for the treatment, prevention and diagnosis of Alzheimer's disease. Binding ability is provided by the presence in the formulation of particular natural lipids identified by the Applicant. These comprise a constant component, made up of cholesterol and sphingomyelin, and an additional variable component, made up of selected lipids.

Abstract: The present invention relates to the production of organic acids with yeasts that overexpress at least one sugar transporter. The yeast might express further genes related to the production of the desired organic acid. The organic acid is produced by cultivation of the yeast overexpressing a sugar transporter in an adequate culture medium, whereupon the desired organic acid is accumulated in the culture medium and subsequently purified to the desired degree by techniques known in the art.

Abstract: The invention relates to Seebeck/Peltier bidirectional thermoelectric conversion devices and in particular to devices employing nanowires of conductive or semiconductive material defined on a substrate by common planar technologies.

Abstract: A method of measuring properties of particles includes generating a beam of radiation (IW); illuminating with the beam (IW) an observation region (MR) which is transited by a particle (B). A portion of the beam (IW) gives rise to radiation (SW) which is scattered by scattering interaction with the particle (B), and another portion (TW) is transmitted substantially undisturbed through the observation region (MR). In a detection plane (M), a plurality of radiation intensity values are detected which are determined by the interference between the scattered radiation (SW) and the transmitted radiation (TW). The detection of the radiation intensity values in the detection plane (M) is carried out according to a time sequence of acquisitions corresponding to successive transit positions of the particle through the observation region (MR).

Abstract: Novel melatonin ligands of Formula I: or pharmaceutically acceptable salts thereof wherein: n is 1 or 2; m is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, 6, 7 or 8; v is 2 or 3; A is aryl or heteroaryl; Z is O, S or NR8; Y is selected from the group consisting of hydrogen, aryl, heteroaryl, C1-C6 alkyl, C3-C6 cycloalkyl, and R is selected from the group consisting of hydrogen, hydroxyl, —OCF3, CF3, C1-C8 alkyl, C1-C8 alkyloxy, C1-C8 alkylthio, halogen and —Z—(CH2)p-A; R1 is selected from the group consisting of C1-C4 alkyl, C3-C6 cycloalkyl, CF3, hydroxy-substituted C1-C4 alkyl, hydroxy-substituted C3-C8 cycloalkyl, and NHR5, wherein R5 is C1-C3 alkyl or C3-C6 cycloalkyl; R2 is selected from the group consisting of: hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R3 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R and R3 may be connected together to form an —O—(CH2)v bridge representing with the carbon atoms to which the

Abstract: Procedure for the quantitative determination of interactions of ligands with receptors adsorbed or immobilized on the surface of a solid material which can be functionalized, transparent and with low refractive index, by direct measure of the reflection of light.

Abstract: A blood treatment method is described that is adapted to at least partially eliminate the carbon dioxide content of the type comprising a step of drawing a blood flow. Advantageously according to the invention, the method further comprises the steps of: acidifying the blood flow with transformation of the related blood bicarbonate content into gaseous carbon dioxide; and eliminating the gaseous carbon dioxide content by means of a pressure gradient.

Abstract: The present invention relates to a method for the preparation of a novel hybrid electrochromic coating material with superior performance in terms of transparency, electrochromic contrast, colouration efficiency, and adhesion, for a use in electrochromic devices for applications where a high transparency is required in the bleached state.

Abstract: A method of measuring properties of particles comprises the steps of generating a beam of radiation (IW); illuminating with the beam (IW) an observation region (MR) which is transited by a particle (B), a portion of the beam (IW) giving rise to radiation (SW) which is scattered by scattering interaction with the particle (B), and another portion (TW) being transmitted substantially undisturbed through the observation region (MR); and detecting, in a detection plane (M), a plurality of radiation intensity values which are determined by the interference between the scattered radiation (SW) and the transmitted radiation (TW). The detection of the radiation intensity values in the detection plane (M) is carried out according to a time sequence of acquisitions corresponding to successive transit positions of the particle through the observation region (MR).

Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERN1, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells.

Abstract: The present invention relates to the expression of recombinant nucleic acids in plants. More specifically, the invention provides an Arabidopsis stomatal-specific promoter (AtMYB60 promoter—SEQ ID NO: l)for the selective expression of nucleic acids in stomatal guard cells, gene constructs containing the promoter, expression vectors carrying such and plants transfected therewith. The selective expression of nucleic acids in plant guard cells allows the regulation of stomatal opening/closing states thereby modulating, e. g. increasing, the plant ability to resist to adverse environmental or climatic conditions.

Abstract: The invention discloses compounds of formula I endowed with agonistic activity at the alpha7 nicotinic acetylcholine receptors (?7 nAChRs), a process for the preparation thereof, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological and psychiatric disorders as well as inflammatory diseases.

Abstract: Herein is disclosed a method of generating ascorbic acid from yeast. In one embodiment, the yeast is a Zygosaccharomyces spp. or a Kluyveromyces spp. growing in a medium comprising an ascorbic acid precursor. In a second embodiment the yeast is a recombinant yeast growing in a medium comprising an ascorbic acid precursor. Preferably the recombinant yeast is transformed with a coding region encoding an enzyme selected from L-galactose dehydrogenase (LGDH), L-galactono-1,4-lactone dehydrogenase (AGD), D-arabinose dehydrogenase (ARA), D-arabinono-1,4-lactone oxidase (ALO) or L-gulono-1,4-lactone oxidase (RGLO). The ascorbic acid precursor is preferably D-glucose, L-galactose, L-galactono-1,4-lactone, or L-gulono-1,4-lactone. In another preferred embodiment the ascorbic acid is accumulated in the medium at levels greater than background. Preferably, the yield of the conversion of the precursor to ascorbic acid is preferably at least about 35%.